Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine by Samar Musmar et al.
Musmar et al. Reproductive Biology and Endocrinology 2013, 11:47
http://www.rbej.com/content/11/1/47RESEARCH Open AccessEpidemiology of polycystic ovary syndrome: a
cross sectional study of university students at
An-Najah national university-Palestine
Samar Musmar1*, Asma Afaneh2 and Hafsa Mo'alla2Abstract
Background: Polycystic Ovary Syndrome (PCOS) is the most common gynecological endocrinopathy in women of
reproductive age. Despite its heavy burden on female reproduction and general health, there is no study regarding
PCOS prevalence in Palestine. This study aims to establish prevalence of PCOS among female university students at
An-Najah National University-Palestine and to explore its possible risk factors.
Methods: A cross sectional study was conducted on 137 female students using convenience sampling method for
age group (18–24) years. PCOS cases were identified according to the National Institute of health (NIH) criteria
through clinical interview and assessment for participants at the University clinics. Menstrual irregularities regarding
cycle and flow were identified and clinical hyperandrogenism was assessed as the self-reported degree of hirsutism
using the modified Ferriman Gallwey (mF-G) scoring method of more than 8 score. Biochemical hyperandrogenism
for girls with menstrual irregularities was assessed by measuring free testosterone level. Data were analyzed using
SPSS version 17 applying descriptive methods; different risk factor relationships were estimated using bivariate
analysis and multivariate logistic regression.
Results: The estimated prevalence of PCOS was 7.3% , acne was the only studied risk factor among others to be
statistically significantly related to PCOS patients (OR = 8.430, P-value = 0.015). Clinical Hirsutism was found in 27% of
participants, 70% of whom had idiopathic hirsutism.
Conclusions: Prevalence of PCOS in Palestine seems to be relatively high but similar to other Mediterranean
statistics. We recommend further studies using wider age group and larger sample for all parts of Palestine in order
to generalize results.
Keywords: Polycystic ovary syndrome, PCOS, Prevalence, PalestineBackground
Polycystic ovary syndrome (PCOS) is the most common
endocrine disease among women in reproductive age; it is
defined as a chronic condition of anovulation or oligo-
ovulation with clinical or biochemical hyperandrogenism,
which occurs in the absence of any other underlying con-
dition [1]. Women with PCOS are at increased risk of re-
productive problems including infertility or subfertility,
endometrial cancer and gestational problems. Also may
have metabolic disorders including obesity, metabolic* Correspondence: smusmar@najah.edu
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reproduction in any medium, provided the orsyndrome, type 2 diabetes mellitus, dyslipidemia, hyper-
tension and cardiovascular diseases [1].
Until recently, no universally accepted clinical definition
existed for PCOS, which remains a syndrome, and as such
no single diagnostic criterion is sufficient for clinical diag-
nosis. The initial National Institute of Health (NIH) diag-
nostic criteria based on oligomenorrhea, amenorrhea and
clinical or biochemical hyperandrogenism were broadened
in the 2003 Rotterdam criteria to include PCO findings at
ultrasound. More recently the Androgen Excess Society
(AES) suggested that the diagnostic criteria should be
modified to exclude those with PCO on ultrasound and
oligomenorrhea/amenorrhea but no hyperandrogenism
[2-4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients with polycystic ovary syndrome who
met individual diagnostic criteria according to the
National Institute of Child Health*
Criteria N (%)
Clinical and/or biochemical hyperandrogenism 10 (100%)
Hirsutism score ≥8 10 (100%)
Acne 8 (80%)
Increased free testosterone 0 (0%)
Oligo-ovulation 10 (100%)
Chronic oligomenorrhea and/or amenorrhea 10 (100%)
Exclusion of secondary causes 10 (100%)
*Values are raw numbers (percentages).
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using NIH criteria estimated the prevalence of PCOS at
a range of 4-8% [5-11]. Only few studies were done to
estimate the prevalence of PCOS in the middle east; two
large Iranian studies found prevalence to be around 7%
[12,13] , however to the best of our knowledge no study
was found to estimate PCOS among Arab women. The
objective of this study was to determine the prevalence
of PCOS among female university students in Palestine
according to the National Institute of health (NIH) cri-
teria and to explore its risk factors.
Methods
Study design and the sampling method
A cross-sectional, non-interventional, descriptive and
analytical study was conducted during the period of
November 2011- March 2012 at An-Najah National
University student clinics. Located in Nablus city in the
north of West Bank/Palestine, this largest university at-
tracts students from all social classes and from different
parts of West Bank. A convenient study sample of 136
participant was calculated using Finite Population Cor-
rection formula [14]. Recruitment for the study was
done using proper advertisement by posters and student
electronic boards targeting all female university students.
Of 147 students who agreed to participate, ten (6.8%)
students who did not meet inclusion criteria were ex-
cluded (found to have hyperprolactinemia, taking oral
contraceptives or being pregnant).No one had to be ex-
cluded because of other exclusion criteria (using insulin
sensitizers, having clinical Cushing disease, or having
diabetes).
Study protocol
During the study period, two trained researchers
interviewed recruited participants at the university clinic.
After thoroughly explaining the research and its purpose
to every participant, a written consent form was obtained
followed by completing a checklist datasheet which is
based on the inclusion and exclusion criteria about main
features of PCOS including menstrual history, hirsutism
scoring and some important risk factors. All participants
underwent clinical examinations, including body weight,
height, waist circumference (WC), and hip circumferences
(HC). Waist hip ratio (WHR) was calculated and Body
mass index (BMI) was calculated as weight in kilograms
divided by the height in meters squared (kg/m2) [15]. BMI
values were categorized as underweight (less than 18.5),
normal (18.5-24.9), overweight (25–29.9), and obese
(equal or more than 30) [15].
Of those who had menstrual irregularities (n = 35 ), 33
agreed to undergo venous blood sampling for hormonal
analysis including serum free testosterone (FT), prolactin
(PLC) and thyroid stimulating hormone (TSH). Bloodsamples were centrifuged after 5 minutes of withdrawal,
the serum was preserved in iced refrigerator, and then
samples were sent daily to a standard diagnostic labora-
tory in ice bag for analysis.
Definitions
PCOS diagnosis in this study was defined according to
1990 Consensus of National Institute of Health (NIH)
criteria [2] which requires a PCOS case to have
oligomenorrhea or amenorrhea, clinical and/or bio-
chemical evidence of hyperandrogenism, and exclusion
of other disorders that can result in menstrual irregular-
ities and hirsutism. A participant was considered to have
oligomenorrhea if she had less than 8 cycles per year
and amenorrhea if she had absence of menses for
6 months or more [1]. This was estimated by recalling
menstrual pattern in the last year. Clinical hyperan-
drogenism was diagnosed by hirsutism assessment using
mF-G scoring system figures; we considered the partici-
pants to have hirsutism if they scored 8 or more [16].
This cut off point was used by most of the studies
especially those done in Mediterranean region or on
Caucasian populations. Idiopathic hirsutism (IH) was
defined as clinical hirsutism without menstrual irregular-
ities [17]. Biochemical hyperandrogenism was diagnosed
by elevated levels of serum FT as it is considered the sin-
gle most predictive evidence of hyperandrogenemia
[18,19].
We excluded Cushing syndrome clinically by the ab-
sence of gross clinical features. Serum PLC and TSH
were done for all the participants with menstrual irregu-
larities to exclude hyperprolactinemia and thyroid
hormone disturbances as other causes of menstrual
irregularities.
Lab measurements
Serum FT level was measured using Gamma counter
(Wallac) with a principle of competitive radioimmuno-
assay; normal values were at a range of 0.2-4.1 pg/ml.
TSH test was done using Abbott Axsym- Autommated
Table 2 Anthropometric and gynecologic characteristics of the study sample in relation to PCOS
Anthropometric Total sample Non-PCOS group PCOS group P value*
characteristics (mean ± SD) (mean ± SD) (mean ± SD)
Weight(kg) 58.24 ±9.44 58.09 ±9.41 60.19 ±10.14 0.539
Height(cm) 161.83 ±6.17 161.94 ±6.27 160.5 ±4.82 0.394
WC (cm) 80.42 ±7.49 80.45 ±7.51 80.08 ±7.69 0.885
HC (cm) 97.04 ±7.38 96.91 ±7.33 98.62 ±8.16 0.537
W/H ratio 0.83 ±0.047 0.830 ±0.047 0.813 ±0.0516 0.318
BMI(kg/m2) 22.2 ±3.13 22.11 ±3.06 23.37 ±3.85 0.333
BMI classes Total sample N (%) Non-PCOS group N (%) PCOS group N (%) P value*
Underweight (less than18.5) 15 (10.9) 14 (11) 1(10) 1.00
Normal (18.5-24.9) 97 (70.8) 91 (71.7) 6(60) 0.47
Overweight (25–29.9) 24 (17.5) 21 (16.5) 3(30) 0.380
Obese (equal or more than30) 1 (0.7) 1 (0.8) 0(0) 1.000
Gynecologic characteristics Total sample N (%) Non-PCOS group N (%) PCOS group N (%) P value*
Hirsutism (mFG more than 8) 38(27.7) 28(22) 10(100) <0.001
Menstrual irregularities 35(25.5) 25(19.7) 10(100) <0.001
*P value less than 0.05 was considered statistically significant.
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II which is based on microparticle enzyme immunoassay
; normal values were ranging at 0.39-4.0 mIU/L. PLC
values were also measured applying Abbott Axsym-
Autommated Immunoassay analyzer which is based on
microparticle enzyme immunoassay; normal values
ranged between 4.1-28.9 ng/ml. All laboratory tests were
done at a standard diagnostic lab which uses internal
quality control for all results. The coefficient of variance
was 2.5% for PLC, 5% for TSH,and 10% for FT.
Statistical analysis
Participants were divided into PCOS group and Non-
PCOS group. Comparison between the two groups was
done applying independent sample T test for continuous
variables and Fisher exact Chi square for categorical var-
iables. P values were considered statistically significant
at P equal or less than 0.05. Multivariate logistic regres-
sion was used to re-examine the significance of the rela-
tionship between PCOS and risk factors and to controlTable 3 Relationship between possible risk factors and PCOS




Frontal baldness 5 3.6%
family history of PCOS 4 2.9%
Hirsutism in mother 17 12.4%
Menstrual disorders in mother 11 8%
* P value less than 0.05 was considered significant calculated by Fisher exact test.confounders. Statistical analysis was done using the Stat-
istical Package for Social Sciences (SPSS) version 17.
Ethical considerations
An-Najah National University IRB Committee approved
the study proposal on Nov 20, 2011, and a written in-
formed consent was obtained from every participant. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal.
Results
Of 147 who agreed to participate in the study, 137 who
met the inclusion criteria were enrolled and completed
the study procedure. All the participants were within the
age group (18–24) with mean age of 20.2 ± 1.4. Only
four of the participants were married and one was
divorced; all of which have no fertility problems. About
smoking, 27 of the participants reported regular
cigarette or water pipe smoking (19.7%). Participants’
weight range was 39.4-82 Kg with the mean ofin the study sample
Non-PCOS group PCOS group P
value*N (%) N (%)
43 33.9% 8 80% 0.006
25 19.7% 2 20% 1.000
3 2.4% 2 20% 0.043
4 3.1% 0 0% 1.000
16 12.6% 1 10% 1.000
10 7.9% 1 10% 0.598
Table 4 Relationships between PCOS and risk factors after adjustment for the confounding factors
Risk factor Exp (B) 95% CI
(P-value)*(odds ratio) (lower, upper)
Acne 8.43 (1.52, 46.82) 0.015
Frontal baldness 8.34 (0.98, 70.66) 0.052
Menstrual irregularities in mother 1.93 (0.18, 20.75) 0.586
Hirsutism in mother 0.67 (0.07, 6.26) 0.727
Smoking 1.62 (0.28, 9.14) 0.588
* P value less than 0.05 was considered significant calculated by logistic regression.
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16.8-30.6 and a mean of 22.2 ±3.1.The prevalence of polycystic ovary syndrome
Out of 137 study participants, 10 students met the NIH
criteria for diagnosis of PCOS making the prevalence
rate to be 7.3% (95% CI 4.7-9.9). None of these cases
had been diagnosed or treated for PCOS; Table 1 shows
that all PCOS cases had oligo-ovulation and clinical
hyperandrogenism (100% had Hirsuitism score ≥8, 80%
had acne, however none had abnormal serum FT levels).
Menstrual irregularities were found in 35 cases of the
137, of which 25 cases had menstrual irregularities with-
out hirsutism. Clinical hirsutism assessed by the mF-G
score was found in 38 cases of this study , of whom 28
had idiopathic hirsutism.Anthropometric characteristics of the sample
There was no significant statistical relation between
PCOS group and non-PCOS group regarding weight,
WC, WHR and BMI means applying independent sam-
ples T test; BMI classes also did not show any significant
statistical relationship with PCOS, (Table 2).Table 5 Biochemical features of Menstrual irregularity
cases (calculated mean) n = 33
Lab test All MI* MI (no PCOS) MI with PCOS P
value**(mean ± SD) (mean ± SD) (mean ± SD)
FT (conv.) 0.95 ±0.42 0.98 ±0.39 0.86 ±0.47 0.49
TSH (SI) 1.25 ±0.66 1.29 ±0.64 1.16 ±0.73 0.66
Prolactin 15.93 ±14.37 17.27 ±16.63 12.87 ±6.62 0.29
(Conv.) (Median 13.4) (Median 14.1) (Median 10.4)
*MI: menstrual abnormalities.
**P value less than 0.05 was considered statistically significant.Risk factors of PCOS
PCOS and non-PCOS groups were studied in relation to
many possible risk factors including acne, smoking, pres-
ence of frontal baldness, family history of PCOS, men-
strual disorders in mothers and hirsutism in mothers.
Applying Fisher Exact test, it was found that about 80%
of PCOS group had acne and 20% had frontal baldness
compared to non-PCOS group (33.9%, and 2.4%) with a
significant statistical difference in both cases (Table 3).
To adjust for participants’ confounding factors, this re-
lationship was reexamined by using multivariate logistic
regression method (Table 4). Family history of PCOS
could not be controlled for confounders because there
were no cases in the PCOS group with this risk factor.
Only acne remained statistically significant (P = 0.017,
OR = 8.06, CI: 1.45-44.75); however, frontal baldness be-
came non-significant (P-value = 0.052, OR = 8.16).Biochemical features of participants with menstrual
irregularities (MI)
Calculated means of FT, TSH and prolactin test results
of 33 participants who had menstrual irregularities were
analyzed. Although some of the results were abnormal
(one case of low TSH and two cases of high prolactin
levels), there was no statistically significant relationship
of these results to PCOS (Table 5).
Discussion
The prevalence of PCOS at An-Najah National Univer-
sity in age groups 18–24 years was found to be 7.3%.
PCOS prevalence depends on the recruitment process of
the study population and criteria used for its definition;
using NIH criteria, two Iranian studies found PCOS
prevalence to be 7.1% and 7%. The first was done in
2011 on a community sample of age group 18–45 years
[12], and the second one was done in 2009 in Isfahan
among females referred to the mandatory pre-marriage
screening clinic of age 17–34 years [13]. Shared common
ethnic and sociodemographic factors between Iranian
and Palestinian women might explains this similarity in
PCOS prevalence in addition to using the same criteria
of diagnosis in the study despite the differences in age
group and sampling methods. Using same criteria for
diagnosis in other parts of the world found a close range
of PCOS prevalence; examples are Australia 8.7%, Spain,
6.5%, Greek Island of Lesbos 6.7%, the southeastern
United States 4%, and Sweden 4.8% [5-9]. Clinical hirsut-
ism in this study was found in 27% of participants
(Table 2), about 70% of whom had idiopathic hirsutism;
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nosis of PCOS, because they may have been oligoovula-
tory, despite their reported regular episodes of vaginal
bleeding.
It is expected that we will have double the prevalence
of PCOS if we use Rotterdam criteria for diagnosis [13];
although this is a newer criteria for diagnosis, many au-
thors argue that its use may overestimate the prevalence
of PCOS. Disagreement has persisted regarding whether
the two additional phenotypes (oligo-ovulation with
PCO or hyperandrogenism with PCOS) in Rotterdam
criteria actually do have classical PCOS, because PCO
on ultrasound is a very common finding in normal
population [20]. Also in some studies they found that
using NIH criteria predicts the metabolic risk more ap-
propriately than Rotterdam criteria [21].
When we explored acne as possible risk factors for
PCOS [22], 80%. of PCOS group were found to have
acne, and having acne was found to increase risk to de-
velop PCOS by eight times (Tables 3 and 4). This is con-
sistent with findings of Turkish and American PCOS
studies where women with PCOS had acne at a rate of
53% [23,24].
Although we found frontal baldness in 20% of PCOS
group, this was not statistically significant after adjust-
ment for confounders (Table 4). Frontal baldness is usu-
ally found in disorders associated with higher levels of
androgen such as androgen secreting tumors [25]. This
is supported by our finding of all PCOS group to have
normal FT serum level (Table 5).
Smoking, history of hirsutism and history of irregular
menses in mothers were found to be insignificantly re-
lated to the presence of PCOS (Tables 3 and 4). These
finding are shared by some studies [5] but not by others
[26]; differences in population characteristics, method-
ology and sample size might explain these finding differ-
ences. Of those who had menstrual abnormalities there
was no statistical biochemical difference between those
who met the definition of PCOS or not (Table 5). Al-
though none of PCOS cases in our study had high serum
FT , clinical hirsutism was significant in all cases using
mF-G score (mean11.8). This is in agreement with
Haung etal [19] who found that supra-normal levels of
FT were present in 57.6% of PCOS patients diagnosed
by NIH criteria. The main strength of this study is that
being the first PCOS prevalence study in Palestine, and
it touches very important women health issue. With the
international criteria of diagnosis used in this study, very
good results about prevalence and risk factors were
drawn that further studies can be built on.
Conclusions
PCOS prevalence is relatively high among young Palestinian
women; the prevalence is similar to Mediterranean andCaucasian populations but higher than that of south East
Asia. Further larger studies in Palestine and Arab countries
are needed to improve diagnosis and control of this com-
mon women health problem.
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